


• Alexander CM., Landsman P.B., Teutsch S.M., Haffner S.M; for the Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP) (2003). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes.* 52: 1210-1214. PMID: 12716754


• Assmann G (2001). Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol. 87: 2A-7B. PMID: 11256848

• Assmann G., Schulte H (1992). Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 70: 733-7. PMID: 1519522


Blasetto J.W., Stein E.A., Brown W.V., Chitra R., Raza A (2003). Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and special population groups. *Am J Cardiol.* 91: 3C-10C. PMID: 12646336


---

X
• Cholesterol and Recurrent Events Trial Investigators (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a


xiv


Davidson M., Ma P., Stein E.A (2002). Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. *Am J Cardiol.* 89: 268-75.


abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. *Arterioscler Thromb Vasc Biol.* 23: 702-3. PMID: 12692010


- **Devaraj S., Kumaresan P.R., Jialal I** (2004). Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. *J Mol Cell Cardiol.* 36: 405-10. PMID: 15010279


- **Ess S.M., Szucs T.D (2001).** Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. *Ital Heart J.* 2: 181-188. PMID: 11305529


xix


xxii


XXV


xxvii


XXX


• Iribarren C., Reed D.M., Chen R., Yano K., Dwyer J.H (1995). Low serum cholesterol and mortality: which is the cause and which is the effect? Circulation. 92: 2396-2403. PMID: 7586337


• Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillan G., Neaton J., Nelson J., Potter J., Rifkind B; for Participants in the Conference on Low


xxxiii


xxxvi


xxxix
of CHD: the Atherosclerosis Risk in Communities (ARIC) Study and the NHLBI Family Heart Study. Genet Epidemiol. 18: 236-50. PMID: 10723108


- Lianqun Jiaa, Shiyin Longb, Mingde Fua, Bingyu Yana, Ying Tianb, Yanhua Xuc, Lantu Goua (2006). Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. Metabolism Clinical and Experimental. 55: 1141-1148. PMID: 16919530


• Lindenstrom E., Boysen G., Nyboe J (1994). Influence of total cholesterol, high-density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen City heart Study. BMJ. 309: 11-15. PMID: 8044059


• McCall A.L (1992). The impact of diabetes on the CNS. Diabetes. 41: 557-70. PMID: 1568525
• McGill H.C., McMahan C.A; and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group (1998). Determinants of atherosclerosis in the young. Am J Cardiol. 82: 30T-6T.


- Neaton J.D., Wentworth D; for the Multiple Risk Factor Interventional Trial Research Group (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. *Arch Intern Med* 152: 56-64. PMID: 1728930


lii


• Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M (2001). C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. *JAMA.* 286: 327-34. PMID: 11466099


Ivii


• Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., Braunwald E (2005). Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 45: 1644-8. PMID: 15893181


- Samia Mora, Paul M Ridker (2006). Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein
Be Used to Target Statin Therapy in Primary Prevention? Am J Cardiol. 97: 33A-41A. PMID: 16442935


lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 35: 871-82. PMID: 8071609


- **Shinji Makita, Motoyuki Nakamura, Kenyu Satoh, Fumitaka Tanaka, Toshiyuki Onoda, Kazuko Kawamura, Masaki Ohswa, Kozo Tanno, Kazuyoshi Itai, Kiyomi Sakata, Akira Okayama, Yasuo Terayama, Yuki Yoshida, Akira Ogawa (2008).** Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. *Atherosclerosis.* [Epub ahead of print.] PMID: 18790479


• Steinhagen-Thiessen E (1994). Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. *Cardiology.* 85*: 244-54. PMID: 7987882


• The European Study Group (1992). Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol. 70: 1281-6. PMID: 1442579

• The ICMR study on Burden of Disease, 2005


• The Pravastatin Multinational Study Group for Cardiac Risk Patients (1993). Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 72: 1031-7. PMID: 8213583


• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult

- Tommasi S., Carluccio E., Bentivoglio M., Buccolieri M., Mariotti M., Politano M., Corea L (1999). C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol. 83: 1595-9. PMID: 10392860

lxix
• Truelsen T., Lindenstrom E., Boysen G (1994). Comparison of stroke between the Copenhagen City Heart study and the Framingham study. Stroke. 25: 802-07. PMID: 8160224


lxxii


* Originals not referred